SB1518
-
Studies show SB1518 is safe and effective for MF
S*BIO ’s phase 1/2 studies for its novel JAK2 inhibitor SB1518 indicate clinical efficacy and good tolerability for the treatment of patients with symptomatic myelofibrosis (MF) and enlarged spleens. SB1518 was also well tolerated in patients …
SB1518 | 04 March 2011
-
EU grants SB1518 orphan drug designation
The European Commission (EC) has granted orphan drug designation to S*BIO SB1518, its potent and orally active JAK2 inhibitor for the treatment of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and postessential thrombocyt…
SB1518 | 04 November 2010
-
S*BIO and Onyx Pharmaceuticals Expand Collaboration for JAK2 Inhibitors
S*BIO and Onyx Pharmaceuticals have announced the expansion of their development collaboration and option and license commercialization agreement for the former’s JAK2 inhibitors, SB1518 and SB1578, also known as ONX 0803 and ONX 0805, respectively…
SB1518 | 19 May 2010
-
S*Bio: Jak2 Inhibitor Demonstrates Safety in Studies for Myeloproliferative Disorder
S*BIO has announced data presentations on its oral JAK2 inhibitor, SB1518. Data will be presented on the clinical results from the Phase 1 dose-escalation trial of SB1518 detailing its safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) …
SB1518 | 09 December 2009
-
S*BIO Commences Phase 1 of Clinical Trial
Singapore-based company S*BIO has initiated phase 1 of the clinical trial for SB1518, a potent and orally-active Janus kinase 2 (JAK2) inhibitor. This is being carried out in medical centers in Australia for patients with chronic idiopathic myelo…
SB1518 | 04 December 2008
-
Singapore company initiates Phase I clinical trials of SB1518
S*BIO has announced the initiation of multi-center Phase I clinical trials of SB1518, a potent and orally-active JAK2 inhibitor, in patients with leukemia and certain types of lymphoma. These comprise of ascending dose studies conducted at severa…
SB1518 | 22 September 2008
